Medicine and Dentistry
Non Muscle Invasive Bladder Cancer
100%
Neoplasm
80%
Diseases
60%
Recurrent Disease
60%
Chemotherapy
40%
Meta-Analysis
40%
Urologist
40%
Intravesical Drug Administration
40%
Bladder Tumor
20%
Patient Population
20%
Pathologist
20%
High Risk Population
20%
Adjuvant Therapy
20%
Subgroup Analysis
20%
Transurethral Resection
20%
Alertness
20%
Carcinoma in Situ
20%
Clinical Trial
20%
Keyphrases
Intermediate Risk
100%
Non-muscle Invasive Bladder Cancer (NMIBC)
100%
Clinical High Risk
40%
Risk Factors
20%
Tumor
13%
Meta-analysis
13%
Previous Treatment
13%
Clinical Practice Guidelines
13%
Risk Category
13%
Bacillus Calmette
13%
Risk Disease
13%
Urologists
13%
Intravesical Therapy
13%
Recurrence Treatment
13%
Clinical Trials
6%
High Risk
6%
Chemotherapy
6%
Risk Stratification
6%
Therapeutic Potential
6%
Control Algorithm
6%
Heterogeneous Groups
6%
Pathologist
6%
Evidence-based Recommendations
6%
Management Recommendations
6%
Clinical Decisions
6%
Clinical Analysis
6%
Low-intermediate Risk
6%
Patient Demographics
6%
Paucity
6%
Adjuvant Therapy
6%
Patient Outcomes
6%
Guideline Recommendations
6%
Subgroup Analysis
6%
Treatment Decisions
6%
Transurethral Resection of Bladder Tumor (TURBT)
6%
Tumor Characteristics
6%
Initial Diagnosis
6%
Carcinoma in Situ
6%
Current Clinical Practice
6%
EORTC
6%
High-grade Tumor
6%
American Urological Association
6%
Literature Practice
6%
Intravesical Chemotherapy
6%
High-risk Disease
6%
Low-risk Disease
6%
Patient Guidelines
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Muscle Invasive Bladder Cancer
100%
Neoplasm
80%
Disease
60%
Recurrent Disease
60%
Chemotherapy
40%
Clinical Trial
20%
Bladder Tumor
20%
Carcinoma in Situ
20%
Neuroscience
Meta-Analysis
100%
Urological
50%
Vigilance
50%
Adjuvant Therapy
50%